Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 plus apatinib in advanced gastric cancer after failure of first-line therapy
ChiCTR2500105855Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Qinghai University
- Start
- Jul 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of trifluridine + tipiracil and Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Affiliated Hospital of Qinghai University. Primary endpoints: DLTs within 28 days, Safety and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilRivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500105855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105855.